An announcement from X4 Pharmaceuticals Inc (XFOR) is now available.
X4 Pharmaceuticals Inc. has posted an update on its corporate presentation, sharing that the FDA has approved XOLREMDI for patients 12 and older with WHIM syndrome. Alongside the approval, X4 launched X4Connect, a support program for U.S. patients, and announced XOLREMDI’s commercial availability through PANTHERx® Rare, with a set annual cost ranging from $372,300 to $496,400. The company provided forward-looking statements on the expected benefits and commercial success of XOLREMDI, while acknowledging potential risks and uncertainties that could impact outcomes.
For an in-depth examination of XFOR stock, go to TipRanks’ Stock Analysis page.
